Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Cytotherapy|September 7, 2024
Expansion of tumor-infiltrating and marrow-infiltrating lymphocytes from pediatric malignant solid tumorsJonathan Metts, Madeline Rodriguez-Valentin, Jonathan Hensel, et al.
Surgery Open Science|December 1, 2025
Collagenolytic <i>Enterococcus faecalis</i> induces DDR1 signaling, proliferation and altered immune infiltrate in colorectal peritoneal metastasesRichard Jacobson, Sean Dineen, John Mullinax, et al.
Annals of Surgical Oncology|January 9, 2008
An aggressive approach to extrahepatic cholangiocarcinomas is warranted: margin status does not impact survival after resectionJonathan Hernandez, Sarah M Cowgill, Sam Al-Saadi, et al.
International Journal of Radiation Oncology, Biology, Physics|March 19, 2023
Neoadjuvant Simultaneous Integrated Boost Radiation Therapy Improves Clinical Outcomes for Retroperitoneal SarcomaCasey L Liveringhouse, Russell F Palm, John M Bryant, et al.
Journal for Immunotherapy of Cancer|January 21, 2025
Art of TIL immunotherapy: SITC's perspective on demystifying a complex treatmentSimon Turcotte, Marco Donia, Brian Gastman, et al.
Oncoimmunology|September 20, 2018
Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancerMichael Poch, MacLean Hall, Autumn Joerger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene CiloleucelRawan Faramand, Michael Jain, Verena Staedtke, et al.
Eclinicalmedicine|June 16, 2025
Defining benchmark values for outcomes of comprehensive resection of primary retroperitoneal liposarcoma: a retrospective multicenter studyFabio Tirotta, Marco Fiore, Sylvie Bonvalot, et al.
Transplantation and Cellular Therapy|December 20, 2025
Safety and efficacy of tumor-infiltrating lymphocyte (TIL) therapy with reduced-dose lymphodepleting conditioning in high-risk metastatic melanoma patientsLilit Karapetyan, Joel Kuriakose, Elizabeth DiMaggio, et al.
Pageof 2